Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | ACACB | O00763 | 13/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14841256 | 0.93 | L3MBTL1 (0.40) | L3MBTL1JAK2ACACBJAK3POLB | |
| SCHEMBL219174 | 0.93 | L3MBTL1 (0.40) | L3MBTL1JAK2ACACBJAK3POLB | |
| SCHEMBL2161071 | 0.93 | JAK2 (0.39) | JAK2JAK3AGBL2 | |
| SCHEMBL1694119 | 0.93 | JAK2 (0.39) | JAK2JAK3AGBL2 | |
| SCHEMBL219175 | 0.93 | L3MBTL1 (0.40) | L3MBTL1JAK2ACACBJAK3POLB | |
| SCHEMBL20303574 | 0.76 | ALDH1A1 (0.36) | L3MBTL1ACACBPOLB | |
| SCHEMBL23666760 | 0.73 | L3MBTL1 (0.47) | L3MBTL1ACACB | |
| SCHEMBL588472 | 0.72 | APLNR (0.48) | L3MBTL1JAK2ACACBJAK3POLB | |
| SCHEMBL588473 | 0.72 | APLNR (0.48) | L3MBTL1JAK2ACACBJAK3POLB | |
| SCHEMBL12069877 | 0.72 | APLNR (0.48) | L3MBTL1JAK2ACACBJAK3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011545-A1 | Chemical Compounds - 759 | ASTRAZENECA AB (SE) | 2015-01-08 | — | — | US | disclosed |
| US-20140155394-A1 | Chemical Compounds - 759 | ASTRAZENECA AB (SE) | 2014-06-05 | — | — | US | disclosed |
| US-20100204246-A1 | 5-AMINOPYRAZOL-3-YL-3H-IMIDAZO (4,5-B) PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204246-A1 | 5-AMINOPYRAZOL-3-YL-3H-IMIDAZO (4,5-B) PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | ABL1, MCL1, ETV6 | L3MBTL1 3959/4885JAK2 4/4885ACACB 2666/4885 |
| US-20150011545-A1 | Chemical Compounds - 759 | MCL1, BCL9, BCL9L | L3MBTL1 4607/4885JAK2 15/4885ACACB 1847/4885 |
| US-20140155394-A1 | Chemical Compounds - 759 | MCL1, BCL9, BCL9L | L3MBTL1 4607/4885JAK2 15/4885ACACB 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.